Product description

MultiBiotic™ is an evidence-based multi-species probiotic specifically designed to target end-organ function and support gastrointestinal health and maintenance. MultiBiotic™ is an ARTG listed medicine and available in Pharmacies and HCP's in AU, NZ, SG and HK. Presently MultiBiotic™ is in Phase 1 clinical trials for chemotherapy induced mucositis and neutropenia. It is listed on the Australian New Zealand Clinical Trials Registry: ACTRN12618000927224

CLINICAL TRIAL: The safety and tolerability of a multi-species probiotic formulation in chemotherapy-induced intestinal mucositis/diarrhoea: an exploratory end-point pilot study. ANZCTR: ACTRN12618000927224KEY

PUBLICATIONS: Thomsen M, Clarke S, Vitetta L 2018. The role of adjuvant probiotics to attenuate intestinal inflammatory responses due to cancer treatments. Article in Press, Beneficial Microbes, 2018 online. 

Palacios T, Vitetta L, Coulson S, Madigan C. D, Lam Y. Y, Manuel R, Briskey D, Hendy C, Kim J, Ishoey T, Soto-Giron M, Schott E. M, Toledo G, Caterson I. 2020. Targeting the Intestinal Microbiota to Prevent Type 2 Diabetes and Enhance the Effect of Metformin on Glycaemia: A Randomised Controlled Pilot Study. Nutrients 2020, 12, 2041; doi:10.3390/nu12072041.

Title: Probiotic compositions and uses thereof for treatment of obesity-related disorders Jurisdiction: Australia Application number: 2015258769 Filing date: 12 May 2015 Status: Under examination
Read more


Sales markets Middle East Region (e.g. UAE); Oceania; North America (USA, Canada); Central America (e.g. Mexico); Europe - EU countries; Europe - non EU (e.g. UK, Russia, ex-CIS countries); South America (e.g. Brazil, Colombia)
Supplied from Australia

Contact information




View all contact information


Curia - From Curiosity to Cure

Curia - From Curiosity to Cure

Alfasigma  Contract Manufacturing Showroom

Alfasigma Contract Manufacturing Showroom

Wavelength Pharmaceuticals

Wavelength Pharmaceuticals

Datwyler Pharma Packaging

Datwyler Pharma Packaging